ClinicalTrials.gg
Active, not recruitingNCT04579367MILOSUpdated Sep 30, 2026

Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

An observational study in Hypercholesterolemia and Mixed Dyslipidemia, sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company. Active, not recruiting at 443 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (part of Daiichi Sankyo) · Observational

How we know

Updated Sep 30, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Hypercholesterolemia by Daiichi Sankyo — 1 open to participants now, 2 under way, 1 of them phase 3. Hypercholesterolemia · Daiichi Sankyo.

Started
2021
the only one that year
Observational
4 of 12
none open now
Registered
9th of 12
by date

Among the 12 studies in Hypercholesterolemia by Daiichi Sankyo, this one is the only one that started in 2021, is one of 4 observational ones, and was the 9th registered.

Hypercholesterolemia

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 12 studies in Hypercholesterolemia by Daiichi Sankyo is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 58 Hypercholesterolemia studies recruiting now, 25 (43%) set no upper age limit and 21 (36%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hypercholesterolemia by Daiichi Sankyo, or all of them as a file.
02

Study summary

The primary objective is to describe in the real-world setting patient characteristics and outcomes of patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia using bempedoic acid and/or its fixed-dose combination with ezetimibe in managing plasma levels of low-density lipoprotein cholesterol (LDL-C).

Secondary objectives are to document and evaluate as applicable:

  • Assessment of the cardiovascular risk of patients treated with bempedoic acid and/or its fixed-dose combination with ezetimibe using different risk scores (e.g. Systematic Coronary Risk Estimation (SCORE) system, SMART score for Very High Risk patients and Framingham risk score for High Risk patients. The scores will be re-calculated during the analysis and used as an analytical tool only).
  • Changes in low-density lipoprotein cholesterol (LDL-C) levels prior to treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe compared to 1 year follow-up and subsequent data collection points, if applicable.
  • Characterize plasma levels of other potentially ASCVD-modifying cholesterol fragments, namely, LDL-C, total cholesterol (TC), apolipoprotein B (apoB), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, triglycerides (TGs) and lipoprotein A (Lp[a]) compared to 1 year follow-up and subsequent data collection points, if applicable.
  • Changes in the levels of inflammatory marker hsCRP compared to 1 year follow-up and subsequent data collection points, if applicable.
  • Adverse Drug Reactions associated to bempedoic acid and/or its fixed-dose combination with ezetimibe.
  • Changes in uric acid levels compared to 1 year follow-up and subsequent data collection points, if applicable.
  • Relevant CV events:

    • Myocardial infarction
    • Unstable angina
    • Coronary artery bypass graft surgery (CABG)
    • Percutaneous transluminal coronary angioplasty (PTCA)
    • Stroke
    • Transient ischemic attack (TIA)
    • Acute peripheral arterial occlusion
    • All-cause death
    • Cardiovascular (CV)-death
  • Adverse effects associated with lipid-modifying treatment (LMT)

    • Laboratory abnormalities
    • Muscle-associated symptoms
    • New onset and/or worsening diabetes
    • Changes in the patients´ glycemic status over time
  • Site characteristics (sites and practitioners) caring for patients treated with bempedoic acid and/or its fixed-dose combination with ezetimibe.
  • Use of LMTs prior or concomitantly to receiving bempedoic acid and/or its fixed-dose combination with ezetimibe (therapies including combination treatments).
  • Bempedoic acid and/or its fixed-dose combination with ezetimibe treatment parameters such as treatment duration by therapy, dosage, prescription intervals, permanent discontinuations, switches and reasons for these, (concomitant medication, additional therapy/interventions).
  • Healthcare resource use especially consultation visits with specialist, nurse time and hospitalizations as well as patient-reported outcome using EQ-5D-5L and PAM-13.
Read the detailed description

This non-interventional study will be conducted to characterize the risks and benefits of bempedoic acid and/or its fixed-dose combination with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia or mixed dyslipidaemia and to gain insight into the effectiveness (managing plasma levels of low-density lipoprotein cholesterol) as well as safety (clinical events associated with the treatment modalities). Real world evidence will be collected in 5000 participants, treated by specialized as well as non-specialized physicians in hospitals and office based centers.

03

Conditions studied

  • Hypercholesterolemia
  • Mixed Dyslipidemia

Keywords

  • Hypercholesterolemia
  • Mixed dyslipidemia
  • Bempedoic acid and/or its fixed-dose combination with ezetimibe
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include participants with primary hypercholesterolemia or mixed dyslipidemia who are being treated with bempedoic acid and/or its fixed dose combination with ezetimibe.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written to participate
  • At least 18 years of age
  • Participants suffering from documented primary hypercholesterolemia or mixed dyslipidemia treated or intended to be treated with bempedoic acid and/or its fixed dose combination with ezetimibe at the discretion of the physician are appropriate for participation in the observation.
  • No exist according to the SmPC of bempedoic acid and/or its fixed-dose combination with ezetimibe
  • No concurrent participation in an interventional study (simultaneous participation in other non-interventional study is possible)
  • > 1 year

Exclusion criteria

Exclusion Criteria:

  • As this is a non-interventional study, no explicit exclusion criteria are defined. The prescribing behavior will not be influenced. Only patients will be included where the decision has been made by the treating physician to treat the patients either with bempedoic acid and/or its fixed-dose combination with ezetimibe.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Bempedoic acid and/or fixed-dose combination with ezetimibe

    Participants with primary hypercholesterolemia or mixed dyslipidemia who received bempedoic acid and/or its fixed-dose combination with ezetimibe.

    Drug: Bempedoic acid and/or its fixed-dose combination with ezetimibe

Interventions

  • DrugBempedoic acid and/or its fixed-dose combination with ezetimibe

    This is a non-interventional study. No study medication will be provided to the patients. Medication will be prescribed by the treating physician in line with the clinical practice.

06

What researchers measure

Primary outcomes

  1. Summary of patient characteristics in patients with primary hypercholesterolemia or mixed dyslipidemia following treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe

    Time frame: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)

Secondary outcomes

  1. Overview of the cardiovascular risk of patients with primary hypercholesterolemia or mixed dyslipidemia following treatment with bempedoic acid/ and/or its fixed-dose combination with ezetimibe

    Cardiovascular risk scores will be assessed using the Systematic Coronary Risk Estimation (SCORE) system, Second manifestations of arterial disease (SMART) and Framingham risk scores. The SMART risk score will estimate 10-year risk for very high-risk participants based on clinical patient characteristics. The gender-specific Framingham risk score will be used to estimate 10-year cardiovascular risk for high-risk participants.

    Time frame: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)

  2. Summary of changes in plasma low-density lipoprotein cholesterol levels following treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe in patients with primary hypercholesterolemia or mixed dyslipidemia

    Time frame: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)

  3. Summary in changes in plasma levels of atherosclerotic cardiovascular disease-modifying cholesterol fragments following treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe

    Plasma levels of total cholesterol (TC), apolipoprotein B (apoB), high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs) and lipoprotein a (Lp\[a\]) will be assessed.

    Time frame: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)

  4. Summary of changes in plasma inflammatory marker hsCRP levels following treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe in patients with primary hypercholesterolemia or mixed dyslipidemia

    Inflammatory status was assessed using high-sensitive C-reactive protein.

    Time frame: Baseline (date of signed informed consent) up to 1 year minimum or 2 year maximum follow up (depending on the availability of bempedoic acid in countries)

07

Study locations

443 sites
  • Dr. Armin Öhlinger Kardiologe & innere Medizin
    Dornbirn, 6850, Austria
  • Landeskrankenhaus Feldkirch
    Feldkirch, 6807, Austria
  • LKH-Univ. Klinikum Graz
    Graz, 8036, Austria
  • Medizinische Universität Graz
    Graz, 8036, Austria
  • Internist Dr. med. univ. Stefan Moser
    Hörsching, 4063, Austria
  • Medizinische Universität Innsbruck
    Innsbruck, 6020, Austria
  • KABEG Klinikum Klagenfurt am Wörthersee
    Klagenfurt, 9020, Austria
  • Konventhospital der Barmherzigen Brüder Linz
    Linz, 4020, Austria
  • Ordination Dr. Johannes Föchterle
    Linz, 4040, Austria
  • Ordination Frau Prof. Dr. Yvonne Winhofer-Stöckl
    Mattersburg, 7210, Austria
  • Kompetenz-Zentrum Diabetes
    Salzburg, 5026, Austria
  • Ordination Universitätsdozent Dr. Alexander Kober
    Sankt Aegyd am Neuwalde, 3193, Austria
  • Ordination Dr. med. univ. Evelyn Fließer-Görzer
    Sankt Stefan ob Stainz, 8511, Austria
  • Ordination Dr. Thomas Maca
    Vienna, 1010, Austria
  • Klinik Hietzing, Wiener Gesundheitsverbund
    Vienna, 1030, Austria
  • Zentrum für Klinische Studien Dr. Hanusch GmbH
    Vienna, 1060, Austria
  • Allgemeines Krankenhaus der Stadt Wien
    Vienna, 1090, Austria
  • Univ.-Prof. Dr. Thomas Stulnig
    Vienna, 1130, Austria
  • Herz Zentrum Währing
    Vienna, 1180, Austria
  • Karl Landsteiner Institut für kardiovaskuläre und intensivmedizinische Forschung
    Vienna, 1210, Austria
  • ASZ
    Aalst, 9300, Belgium
  • Clinique Saint-Luc Bouge Namur
    Bouge, B-5005, Belgium
  • Epicura Hornu
    Boussu, B-7301, Belgium
  • A.Z. KLINA Brasschaat
    Brasschaat, B-2930, Belgium
  • Clinique Saint-Jean Bruxelles
    Brussels, B-1000, Belgium
  • CHU Brugman
    Brussels, B-1020, Belgium
  • CUB-Hôpital Erasme
    Brussels, B-1070, Belgium
  • UZ Brussel
    Brussels, B-1090, Belgium
  • Clinique de l'Europe Saint Elisabeth
    Brussels, B-1180, Belgium
  • UCL Saint-Luc Woluwé Bruxelles
    Brussels, B-1200, Belgium
  • Private Practice
    Ciney, B-5590, Belgium
  • Az Sint Blazius
    Dendermonde, 9200, Belgium
  • UZ Antwerpen
    Edegem, B-2650, Belgium
  • Z.O.L - Campus St. Jan
    Genk, B-3600, Belgium
  • AZ St-Lucas & Volkskliniek
    Ghent, B-9000, Belgium
  • UZ Gent
    Ghent, B-9000, Belgium
  • GHDC Charleroi - Site Hôpital Saint-Joseph
    Gilly, B-6060, Belgium
  • Private Practice
    Gribomont, B-6887, Belgium
  • Pôle hospitalier Jolimont
    Haine-Saint-Paul, B-7100, Belgium
  • BVBA Med Kab
    Halen, B-3545, Belgium
  • Jessa Ziekenhuis
    Hasselt, B-3500, Belgium
  • CHR Huy
    Huy, B-4500, Belgium
  • JAN YPERMAN Ziekenhuis
    Ieper, B-9800, Belgium
  • AZ Groeninge Kortrijk
    Kortrijk, B-8500, Belgium
  • CHU Tivoli
    La Louvière, B-7100, Belgium
  • UZ Leuven
    Leuven, B-3000, Belgium
  • CHR Citadelle de Liège
    Liège, B-4000, Belgium
  • CHU Liège
    Liège, B-4000, Belgium
  • CHU Charleroi Hopital civil Marie-Curie
    Lodelinsart, B-6042, Belgium
  • CHU Mons Ambroise Paré
    Mons, B-7000, Belgium
  • AZ Sint Jan
    Ostend, B-8400, Belgium
  • AZ Delta
    Roeselare, B-8800, Belgium
  • AZ Glorieux
    Ronse, B-9600, Belgium
  • Sint Trudo
    Sint-Truiden, B-3800, Belgium
  • Sint-Andriesziekenhuis Tielt
    Tielt, B-8700, Belgium
  • CHU UCL Mont-Godinne
    Yvoir, B-5530, Belgium
  • Downtown Clinic Aachen
    Aachen, 52062, Germany
  • Praxis Delonge
    Aachen, 52078, Germany
  • Praxis Osterziel
    Amberg, 92224, Germany
  • MVZ Helios Aue
    Aue, 08280, Germany
  • Kardiologische Praxis Enders
    Bad Elster, 08645, Germany
  • SLK-Klinikum am Plattenwald
    Bad Friedrichshall, 74177, Germany
  • Herzcarre Praxis
    Bad Homburg, 61348, Germany
  • Kardiologische Praxis
    Bad Homburg, 61348, Germany
  • Zentrum für klinische Forschung
    Bad Homburg, 61348, Germany
  • Universitätsklinikum Freiburg - Universitäts-Herzzentrum
    Bad Krozingen, 79189, Germany
  • Praxis am Landratspark
    Bad Segeberg, 23795, Germany
  • Hausärzte am Spritzenhaus
    Baiersbronn, 72270, Germany
  • CIMS Studienzentrum Bamberg GmbH Drs. Kirschner/Haas/Ritzel
    Bamberg, 96049, Germany
  • Kardiologische Praxis
    Bechhofen, 66894, Germany
  • Praxis Rankestraße
    Berlin, 10789, Germany
  • SKP Studienzentrum der kardiologischen Praxisgemeinschaft Rankestrasse GmbH
    Berlin, 10789, Germany
  • Herzpraxis Berlin MVZ
    Berlin, 12165, Germany
  • Charité - Universitätsmedizin Berlin
    Berlin, 12203, Germany
  • Dres. Seeger & Partner
    Berlin, 12627, Germany
  • Diabetespraxis Dr. Braun
    Berlin, 13187, Germany
  • Lipidambulanz Charite
    Berlin, 13353, Germany
  • Praxiszentrum Biedenkopf
    Biedenkopf, 35216, Germany
  • Praxis Dr. A. Biedermann
    Blankenhain, 99444, Germany
  • Kardiologische Gemeinschaftspraxis Bremerhaven
    Bremerhaven, 27574, Germany
  • Kardiologie im Friedrichspalast Bruchsal
    Bruchsal, 76646, Germany
  • MediClin Reha-Zentrum Spreewald
    Burg, 03096, Germany
  • Studiengesellschaft Könemann und Steinmann GbR
    Bünde, 32257, Germany
  • MVZ am Küchwald
    Chemnitz, 09113, Germany
  • Kardiologische Praxis Stellmach
    Chemnitz, 09126, Germany
  • MVZ Polymed
    Chemnitz, 09130, Germany
  • Uniklinik Köln
    Cologne, 50937, Germany
  • Zentrum für klinische Forschung
    Cologne, 51069, Germany
  • IKAPP
    Cologne, 51105, Germany
  • Praxis Dr. Menzel
    Dessau, 06846, Germany
  • Klinikum Lippe GmbH
    Detmold, 32756, Germany
  • Kardiologische Gemeinschaftspraxis
    Dortmund, 44137, Germany
  • Cardiologicum Dresden/Pirna
    Dresden, 01277, Germany
  • Hausärztliche Gemeinschaftspraxis mit diabetologischem Schwerpunkt
    Dresden, 01279, Germany
  • Dres. Günther/Kolschmann
    Dresden, 01307, Germany
  • Herzzentrum Dresden, Universitätsklinik an der Technischen Universität Dresden
    Dresden, 01307, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • DZDM Diabeteszentrum Duisburg Mitte
    Duisburg, 47051, Germany
  • Nierenzentrum Düren
    Düren, 52351, Germany
  • Universitätsklinikum Düsseldorf
    Düsseldorf, 40225, Germany

Showing the first 100 of 443 sites across 8 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Oct 2026, 69 months after the start.

Of 51 observational studies under Hypercholesterolemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 59. This study's planned 69 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2020
First posted
Oct 8, 2020
StartActual
Jan 15, 2021
Primary completionEst.
Oct 30, 2026
CompletionEst.
Oct 30, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 Spain)
  • Hospital UNiversitario la Princesa · Madrid, Spain
  • Hospital Universitario Virgen de la Victoria · Málaga, Spain
Show 2 removed
  • Hospital Universitario la Princesa · Madrid, Spain
  • Hospital Universitario Virgen de La Victoria · Málaga, Spain
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Spain)
    • Hospital UNiversitario la Princesa · Madrid, Spain
    • Hospital Universitario Virgen de la Victoria · Málaga, Spain
    Show 2 removed
    • Hospital Universitario la Princesa · Madrid, Spain
    • Hospital Universitario Virgen de La Victoria · Málaga, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04579367
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Jan 15, 2021
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Sep 30, 2026

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion